EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A Prospective Observational Study on the Clinical Safety and Efficacy of Sacubitril and Valsartan in Heart Failure Management

Suraj Kumar G, Dharma Raju G, Rama Krishna B, Sridhar G, Manjula B

Asian Journal of Hospital Pharmacy · 18.07.2026 · 9-16

DOI: 10.38022/ajhp.v6i2.143 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Asian Journal of Hospital Pharmacy, online erschienen am 18.07.2026. Verfasst von Suraj Kumar G und 4 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heart failure is a major cardiovascular disorder affecting millions of people worldwide and is associated with high morbidity, mortality, and frequent hospitalisation. Reduced ejection fraction (EF) is a significant indicator of disease severity and poor prognosis. The combination of Sacubitril and Valsartan has emerged as an effective therapeutic option for improving cardiac function and reducing hospitalisation in heart failure patients. The present prospective observational study was conducted to evaluate the safety and efficacy of sacubitril/valsartan in heart failure management over a period of six months at Gleneagles Hospitals. A total of 60 patients diagnosed with heart failure and reduced ejection fraction were included in the study. Patient data were collected from case records, prescriptions, laboratory reports, and medication history. Demographic distribution showed a higher prevalence among males (62%) compared to females (38%), with the majority of patients belonging to the age group of 61–70 years (33.33%). Out of 60 patients, 52 (87%) showed improvement in ejection fraction after initiation of sacubitril/valsartan therapy, indicating significant therapeutic efficacy. Furthermore, 50 patients (83.33%) demonstrated reduced frequent hospitalisation and improved quality of life. Safety evaluation revealed that 50 patients experienced no adverse drug reactions, while only 10 patients reported mild adverse effects such as hyperkalemia, angioedema, hypotension, and renal impairment. The findings conclude that sacubitril/valsartan therapy significantly improves ejection fraction, reduces hospital admissions, and provides a favourable safety profile in heart failure patients.

Zitieren

APA

G, S. K., G, D. R., B, R. K., G, S., & B, M. (2026). A Prospective Observational Study on the Clinical Safety and Efficacy of Sacubitril and Valsartan in Heart Failure Management. Asian Journal of Hospital Pharmacy, 9-16. https://doi.org/10.38022/ajhp.v6i2.143

Vancouver

G SK, G DR, B RK, G S, B M. A Prospective Observational Study on the Clinical Safety and Efficacy of Sacubitril and Valsartan in Heart Failure Management. Asian Journal of Hospital Pharmacy. 2026:9-16. doi:10.38022/ajhp.v6i2.143

BibTeX
@article{G2026,
  author = {G, Suraj Kumar and G, Dharma Raju and B, Rama Krishna and G, Sridhar and B, Manjula},
  title = {A Prospective Observational Study on the Clinical Safety and Efficacy of Sacubitril and Valsartan in Heart Failure Management},
  journal = {Asian Journal of Hospital Pharmacy},
  year = {2026},
  pages = {9--16},
  doi = {10.38022/ajhp.v6i2.143}
}
Kostenlos starten →